A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)

Clinical trial NCT04438083 · TERMINATED

Trial details

NCT number: NCT04438083
Sponsor: CRISPR Therapeutics AG
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Renal Cell Carcinoma

Start date: 2020-06-16
Primary completion: 2024-10-08
Enrollment: 19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.